gms | German Medical Science

55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

25. bis 28.04.2004, Köln

Experimental gliossarcoma genetic therapy: Use of a silicon formulation with ganciclovir

Experimentelle Gliossarkoma-Therapie: Gebrauch von einer Silikon-Formulierung mit Ganciclovir

Meeting Abstract

  • F. K. Miura - Neurosurgery Department of Sao Paulo University Medical School, Sao Paulo /BR
  • corresponding author Tobias Alecio Mattei - Neurosurgery Department of Sao Paulo University Medical School, Sao Paulo /BR
  • S. K. N. Marie - Neurosurgery Department of Sao Paulo University Medical School, Sao Paulo /BR
  • T. Hayakawa - Genetic Therapy and Molecular Biology Lab., Osaka University, Neurosurgery Department, Osaka /J
  • T. Yoshimini - Genetic Therapy and Molecular Biology Lab., Osaka University, Neurosurgery Department, Osaka /J
  • J. A. Mattei - Neurosurgery Department of Sao Paulo University Medical School, Sao Paulo /BR
  • R. J. Marino - Neurosurgery Department of Sao Paulo University Medical School, Sao Paulo /BR

Deutsche Gesellschaft für Neurochirurgie. Ungarische Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. DocP 05.52

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2004/04dgnc0335.shtml

Veröffentlicht: 23. April 2004

© 2004 Miura et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

- Evaluate the efficiency of a silocone formulation for intratumoral release of ganciclovir in experimental gliossarcoma treated with genetic therapy (enzyme, pro-drug) - Study the biodisponibility and safety of ganciclovir realesed by this silicone formulation, compared with convetional routes of administration

Methods

- Cellular culture and virus production - Preparation of a silicone formulation with ganciclovir (GCV) - Studies of GCV liberation "in vitro" - Essays of citotoxicity of GCV "in vitro" - Implantation "in vivo" of tumoral cells and viral inoculation - Intracerebral distribution of GCV measured by Fase Revertion High Resolution Liquid Cromatography - Statistical evaluation

Results

Sustained release of low dose gangiclovir from a silicone formulation prolonged the survival of rats with gliossarcoma under Herpes Simplex virus thymidine kinase suicide gene therapy.

Conclusions

- Sustained release of low dose gangiclovir from a silicone formulation prolonged significantly the survival of "Fischer 344" rats with gliossarcoma 9L, treated with T1 virus, expressing the thymidine kinase Herpes Simplex 1 enzyme, when compared with the intraperitoneal inoculation of ganciclovir. - The histopathological analysis of the cerebral tissue around the cavity occuped by the silicone formulation suggests that it causes little inflamatory reaction and no imunological reaction. - The biodisponibility study of the ganciclovir released by the silicone formulation shows that the intratumoral concentration of the drug was effective for the studied modell, whereas the blood concentration was indetectable.